Martinelli Giovanni

Martinelli Giovanni

UNVERIFIED PROFILE

Are you Martinelli Giovanni?   Register this Author

Register author
Martinelli Giovanni

Martinelli Giovanni

Publications by authors named "Martinelli Giovanni"

Are you Martinelli Giovanni?   Register this Author

100Publications

2988Reads

48Profile Views

Ponatinib treatment in chronic myeloid leukemia cell lines targets aurora kinase A/FOXM1 axis.

Hematol Oncol 2020 Apr 28;38(2):201-203. Epub 2020 Jan 28.

Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale-DIMES-Istituto di Ematologia "L. e A. Seràgnoli", University of Bologna, Bologna, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hon.2703DOI Listing
April 2020

Linear and circular PVT1 in hematological malignancies and immune response: two faces of the same coin.

Mol Cancer 2020 Mar 30;19(1):69. Epub 2020 Mar 30.

Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, FC, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12943-020-01187-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7104523PMC
March 2020

Identification of a novel large EPCAM-MSH2 duplication, concurrently with LOHs in chromosome 20 and X, in a family with Lynch syndrome.

Int J Colorectal Dis 2019 Nov 26;34(11):1999-2002. Epub 2019 Oct 26.

Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via Piero Maroncelli 40, 47014, Meldola, FC, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00384-019-03414-yDOI Listing
November 2019

Population Pharmacokinetics of Glasdegib in Patients With Advanced Hematologic Malignancies and Solid Tumors.

J Clin Pharmacol 2019 Nov 25. Epub 2019 Nov 25.

Clinical Pharmacology, Global Product Development, Pfizer Inc, San Diego, California, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jcph.1556DOI Listing
November 2019

The balance between mitotic death and mitotic slippage in acute leukemia: a new therapeutic window?

J Hematol Oncol 2019 11 26;12(1):123. Epub 2019 Nov 26.

Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via P. Maroncelli 40, 47014, Meldola, FC, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13045-019-0808-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6880427PMC
November 2019

New generation anaplastic lymphoma kinase inhibitors.

Transl Lung Cancer Res 2019 Nov;8(Suppl 3):S280-S289

Thoracic Oncology Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), IRCCS, Meldola, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/tlcr.2019.09.14DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6894988PMC
November 2019

CAR-T cell therapy: a potential new strategy against prostate cancer.

J Immunother Cancer 2019 Oct 16;7(1):258. Epub 2019 Oct 16.

Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via P. Maroncelli 40, 47014, Meldola, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-019-0741-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6794851PMC
October 2019

Gilteritinib or Chemotherapy for Relapsed or Refractory -Mutated AML.

N Engl J Med 2019 10;381(18):1728-1740

From the Abramson Cancer Center, University of Pennsylvania (A.E.P.), and Thomas Jefferson University (M.K.) - both in Philadelphia; Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Istituto Di Ricovero e Cura a Carattere Scientifico (IRCCS), Meldola (G.M.), L. and A. Seràgnoli Institute of Hematology, Bologna University Medical School, Bologna (S.P.), Ospedali Riuniti Villa Sofia-Cervello, Palermo (F.F.), and IRCCS San Raffaele Scientific Institute, Milan (F.C.) - all in Italy; University of Texas M.D. Anderson Cancer Center, Houston (J.E.C.); Universitätsklinikum Giessen und Marburg, Marburg, Germany (A.N.); Memorial Sloan Kettering Cancer Center, New York (E. Berman); Hospital Universitari i Politècnic La Fe, Valencia, and Centro de Investigación Biomédica en Red Cáncer (CIBERONC), Instituto Carlos III, Madrid - both in Spain (P.M.); University of Maryland Greenebaum Comprehensive Cancer Center (M.R.B.) and Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University (M.J.L.) - both in Baltimore; University of Chicago, Chicago (R.A.L.), and Astellas Pharma, Northbrook (C.L., N. Hasabou, X.L., E. Bahceci) - both in Illinois; University of Minnesota, Minneapolis (C.U.); University of Alabama at Birmingham, Birmingham (H.P.E., A.D.S.); Hollings Cancer Center, Medical University of South Carolina, Charleston (R.S.); University of California, San Francisco, San Francisco (R.O.); National Taiwan University, Taipei City, Taiwan (W.-C.C.); Yale University School of Medicine, New Haven, CT (N.P.); Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Université Toulouse III Paul Sabatier, Toulouse, France (C.R.); Sendai Medical Center, National Hospital Organization, Sendai (H.Y.), and University of Fukui, Fukui (N. Hosono) - both in Japan; Seoul National University (S.-S.Y.) and Asan Medical Center, University of Ulsan College of Medicine (J.-H.L.) - both in Seoul, South Korea; Wake Forest Baptist Medical Center, Winston-Salem, NC (T.P.); and Massachusetts General Hospital, Harvard Medical School, Boston (A.T.F.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1902688DOI Listing
October 2019

Advances in Molecular Mechanisms and Immunotherapy Involving the Immune Cell-Promoted Epithelial-to-Mesenchymal Transition in Lung Cancer.

J Oncol 2019 19;2019:7475364. Epub 2019 Aug 19.

Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2019/7475364DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6721259PMC
August 2019

Aneuploidy: Cancer strength or vulnerability?

Int J Cancer 2019 01 31;144(1):8-25. Epub 2018 Oct 31.

Scientific Directorate, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.31718DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6587540PMC
January 2019

Novel Agents for Acute Myeloid Leukemia.

Cancers (Basel) 2018 Nov 9;10(11). Epub 2018 Nov 9.

Hematology, Department of Biomedicine and Prevention, "Tor Vergata" University of Rome, 00133 Roma, Italy.

View Article

Download full-text PDF

Source
http://www.mdpi.com/2072-6694/10/11/429
Publisher Site
http://dx.doi.org/10.3390/cancers10110429DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6267447PMC
November 2018

Leukemia cutis in a Ph+ ALL patient treated with ponatinib.

G Ital Dermatol Venereol 2018 Oct;153(5):730-731

Unit of Dermatology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.23736/S0392-0488.17.05647-4DOI Listing
October 2018

Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy.

Mol Cancer 2018 02 19;17(1):49. Epub 2018 Feb 19.

Hematology/Oncology "L. e A. Seràgnoli", Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12943-018-0780-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5817796PMC
February 2018

FOXM1 Transcription Factor: A New Component of Chronic Myeloid Leukemia Stem Cell Proliferation Advantage.

J Cell Biochem 2017 11 30;118(11):3968-3975. Epub 2017 May 30.

Department of Experimental, Diagnostic and Specialty Medicine-DIMES, Institute of Hematology L. and A. Seràgnoli-University of Bologna, Bologna, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jcb.26052DOI Listing
November 2017

Blinatumomab in Ph+ B-ALL: present and perspectives.

Oncotarget 2017 Nov 25;8(55):93309-93310. Epub 2017 Oct 25.

Cristina Papayannidis: Institute of Hematology and Medical Oncology "L. and A. Seràgnoli", Department of Experimental, Diagnostic and Specialty Medicine, Bologna University School of Medicine, Bologna, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.22071DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5706793PMC
November 2017

Chibby 1: a new component of β-catenin-signaling in chronic myeloid leukemia.

Oncotarget 2017 Oct 22;8(50):88244-88250. Epub 2017 Sep 22.

Department of Experimental Diagnostic and Specialty Medicine, DIMES-Institute of Hematology "L. and A. Seràgnoli", University of Bologna Medical School, Bologna, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.21166DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5675707PMC
October 2017

The clonal evolution of two distinct T315I-positive BCR-ABL1 subclones in a Philadelphia-positive acute lymphoblastic leukemia failing multiple lines of therapy: a case report.

BMC Cancer 2017 Aug 5;17(1):523. Epub 2017 Aug 5.

Department of Experimental, Diagnostic and Specialty Medicine, Institute of Hematology "L. e A. Seràgnoli", University of Bologna, Via Massarenti, 9-40138, Bologna, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-017-3511-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5545087PMC
August 2017

Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy.

J Clin Oncol 2017 Jun 29;35(17):1905-1912. Epub 2017 Mar 29.

Emanuele Zucca and Franco Cavalli, Oncology Institute of Southern Switzerland, Bellinzona; Luca Mazzucchelli, Cantonal Institute of Pathology, Locarno, Switzerland; Annarita Conconi, Ospedale degli Infermi, Biella; Giovanni Martinelli, European Institute of Oncology; Liliana Devizzi, Fondazione Istituto Nazionale Tumori; Valter Torri, Mario Negri Institute; Andrés J.M. Ferreri, San Raffaele Scientific Institute; Maurilio Ponzoni, San Raffaele Hospital, Milan; Alessandra Tucci, Spedali Civili, Brescia; Umberto Vitolo, University-Hospital Città della Salute e della Scienza, Turin; Maurizio Martelli, Sapienza University; Stefan Hohaus, Catholic University of the Sacred Heart, Rome; Graziella Pinotti, Fondazione Macchi Hospital, Varese; Caterina Stelitano, Bianchi-Melacrino-Morelli Hospitals, Reggio Calabria; Monica Bellei, University of Modena and Reggio Emilia, Modena, Italy; Reda Bouabdallah, Institut Paoli-Calmettes, Marseille; Gilles Salles, Hospices Civils de Lyon and Université Claude Bernard Lyon-1, Pierre-Benite; Catherine Sebban, Centre Léon Bérard, Lyon; Franck Morschhauser, Claude Huriez Hospital, Lille; Anne Moreau, University Hospital of Nantes, Nantes; Hervé Tilly, Centre Henri Becquerel, Rouen; Corinne Haioun, Henri-Mondor Hospital, Paris Créteil; Corinne Haioun, UPEC, Assistance Publique-Hopitaux de Paris; Catherine Thieblemont, Assistance Publique-Hopitaux de Paris, Hôpital-Saint-Louis, Hematooncology-Université Paris Diderot, Sorbonne Paris-Cité, Paris, France; Ruth Pettengell, St George's University of London, London; Andrew Jack, St James's University Hospital, Leeds; Peter Johnson, Southampton General Hospital, Southampton, United Kingdom; Armando Lopez Guillermo and Elias Campo, Hospital Clinic, Barcelona, Spain; Pierre Zachée, ZNA Stuivenberg, Antwerp; and André Bosly, Mont-Godinne UCL, Yvoir, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.70.6994DOI Listing
June 2017

Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study.

J Clin Oncol 2017 Jun 29;35(16):1795-1802. Epub 2017 Mar 29.

Giovanni Martinelli and Cristina Papayannidis, Institute of Hematology and Medical Oncology "L. and A. Seràgnoli", Bologna; Alessandro Rambaldi, University of Milan Hematology and Bone Marrow Transplant Unit, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy; Nicolas Boissel, University Paris Diderot, Hôpital Saint-Louis, Paris; Patrice Chevallier, Centre Hospitalier Universitaire Nantes, Nantes, France; Oliver Ottmann, Cardiff University, Cardiff; Adele K. Fielding, University College London Cancer Institute, London, United Kingdom; Nicola Gökbuget, University Hospital, Goethe University, Frankfurt; Max S. Topp, Universitätsklinikum Würzburg, Würzburg, Germany; Ellen K. Ritchie, Weill Cornell Medical College and New York Presbyterian Hospital, New York, NY; Lulu Ren Sterling, Amgen, San Francisco; Jonathan Benjamin, Amgen, Thousand Oaks; and Anthony Stein, Gehr Family Center for Leukemia Research, City of Hope, Duarte, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.69.3531DOI Listing
June 2017

The relevance of a low JAK2V617F allele burden in clinical practice: a monocentric study.

Oncotarget 2017 Jun;8(23):37239-37249

Department of Experimental, Diagnostic and Specialty Medicine, Institute of Hematology 'L. and A. Seràgnoli', University of Bologna, S. Orsola-Malpighi Hospital, Bologna, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.16744DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5514906PMC
June 2017

Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patients.

Am J Hematol 2017 Jan 12;92(1):37-41. Epub 2016 Nov 12.

Department of Experimental, Diagnostic and Specialty Medicine (DIMES), Institute of Hematology and Clinical Oncology "L. and A. Seràgnoli", Sant'Orsola-Malpighi University Hospital, Bologna, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.24572DOI Listing
January 2017

Efficacy of Azacitidine in the treatment of adult patients aged 65 years or older with AML.

Expert Opin Pharmacother 2016 Dec 21;17(18):2479-2486. Epub 2016 Nov 21.

a Institute of Hematology L. e A. Seràgnoli , Universita degli Studi di Bologna Azienda Ospedaliera Sant\'Orsola-Malpighi Ringgold standard institution , Bologna , Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2016.1258056DOI Listing
December 2016

Nilotinib against high dose imatinib for salvage therapy of chronic myeloid leukaemia.

Lancet Haematol 2016 12;3(12):e554-e555

University of Bologna, Bologna, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2352-3026(16)30170-3DOI Listing
December 2016

P53-MDM2 Pathway: Evidences for A New Targeted Therapeutic Approach in B-Acute Lymphoblastic Leukemia.

Front Pharmacol 2016 16;7:491. Epub 2016 Dec 16.

Scientific Direction, IRCCS - Referral Cancer Center of Basilicata Rionero in Vulture (PZ), Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fphar.2016.00491DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5159974PMC
December 2016

Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia.

N Engl J Med 2016 Aug 12;375(8):740-53. Epub 2016 Jun 12.

From the University of Texas MD Anderson Cancer Center, Houston (H.M.K.); the Dana-Farber Cancer Institute, Boston (D.J.D.), and Pfizer, Cambridge (E.V.) - both in Massachusetts; Universitätsklinikum Münster, Münster (M.S.), and Goethe University, Frankfurt (N.G.) - both in Germany; Institute Seràgnoli, DIMES (Department of Experimental, Diagnostic and Specialty Medicine), University of Bologna, Bologna, Italy (G.M.); Stanford Cancer Institute, Stanford (M.L.), and the University of California, Irvine Medical Center, Orange (S.O.) - both in California; the University of Chicago, Chicago (W.S.); Pfizer, Pearl River, NY (K.W.); Pfizer, Groton, CT (T.W., M.L.P., B.S.); and Cleveland Clinic, Cleveland (A.S.A.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1509277DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5594743PMC
August 2016

Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States.

J Natl Cancer Inst 2016 Jul 4;108(7). Epub 2016 Mar 4.

Affiliations of authors:Department of Health Policy and Management, Johns Hopkins University , Baltimore, MD (WVP); Department of Medicine (RAL) and Departments of Pediatrics and of Public Health Sciences (RMC), University of Chicago, Chicago, IL; Eshelman School of Pharmacy and Gillings School of Global Public Health, Lineberger Comprehensive Cancer Center , and Cecil G. Sheps Center for Health Services Research, University of North Carolina , Chapel Hill, NC (SBD); Department of Haematology, Hammersmith Hospital, Imperial College , London , UK (JFA); Department of Medicine (RH, SS) and Department of Hematology and Oncology (MCM), University of Heidelberg, Mannheim, Germany; Department of Haematology and Oncology, S. Orsola-Malpighi University Hospital (MB), and Department of Hematology, "L. e A. Seragnoli" (GM), University of Bologna , Bologna , Italy ; Department of Haematology and Oncology, University Hospital , Jena , Germany (EE); INSERM Centre d'Investigation Clinique (CIC) 1402, CHU de Poitiers, Poitiers, France (JG, FG); Laboratoire d'Hematologie, Universite Victor Segalen, Bordeaux, Pessac, France (FXM); Department of Internal Medicine, Hematology and Oncology, University Hospital Brno , Brno , Czech Republic (JM); Department of Hematology and Oncology, University Hospital Leipzig , Leipzig , Germany (DN); Barbara Ann Karmanos Cancer Institute, Wayne State University , Detroit, MI (CAS); Department of Medicine, Weill Cornell Medical Center , New York, NY (RTS); Uppsala University , Uppsala , Sweden (BS).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djw003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4948567PMC
July 2016

Present and future of molecular monitoring in chronic myeloid leukaemia.

Br J Haematol 2016 05 7;173(3):337-49. Epub 2016 Mar 7.

Department of Experimental, Diagnostic and Specialty Medicine, Haematology/Oncology "L. e A. Seràgnoli", University of Bologna, Bologna, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.13966DOI Listing
May 2016

Best Practices in Chronic Myeloid Leukemia Monitoring and Management.

Oncologist 2016 05 31;21(5):626-33. Epub 2016 Mar 31.

Department of Experimental, Diagnostic and Specialty Medicine, Hematology/Oncology "L. e A. Seràgnoli," University of Bologna, Bologna, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2015-0337DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4861357PMC
May 2016